Brief: Radiopharm Theranostics Says Positive Guidance From FDA Pre-IND Meeting
29/05/2023 02:30
May 29 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* POSITIVE GUIDANCE FROM FDA PRE-IND MEETING SUPPORTS IND
APPLICATION FOR PHASE 2B/3 CLINICAL TRIAL IMAGING BRAIN
METASTASIS
Source text for Eikon: ID:nASX9W4c5n
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%